US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade
Executive Summary
HHS will take steps to increase access to abortion medication and prevent states from banning it, Secretary Becerra says, but also is questioned about whether the FDA can speed up certification of pharmacies and if the Justice Department would sue states banning access.
You may also be interested in...
Order For Withdrawal Of Mifepristone Would Be ‘Unprecedented,’ Seismic Event; Wyden Says FDA Must Ignore It
Senator Wyden says the case has been "a rigged game all along" as state attorneys general and medical groups file briefs in the suit against the FDA.
What Will FDA Do In Battle Over Medication Abortion Access?
Attorneys discuss host of questions the agency faces in the wake of the Dobbs decision, including whether to take enforcement action against mifepristone REMS violations, whether to change restrictions on its use, and how to deal with challenges to its drug approval authority.
Mifepristone Access Swings In The Balance In Post-Roe World
The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.